Valence8 US’s Intellia Therapeutics NTLA Stock Holding History

Valence8 US’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-13,020	Closed	-$268K	–	46
2024 Q3	$268K	Buy	+13,020	New	+$300K	0.11%	38

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Valence8 US's NTLA Position: Q4 2024 in Review

Valence8 US sold out of Intellia Therapeutics (NTLA) in Q4 2024, closing a stake of 13,020 shares — an estimated $268K sold.

Valence8 US first reported a position in NTLA in Q3 2024 and held it in 1 quarter. The position peaked at $268K in Q3 2024. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2024.

Valence8 US reported no remaining Intellia Therapeutics position as of Q4 2024 after selling out during the quarter.
Valence8 US sold 13,020 Intellia Therapeutics shares in Q4 2024, an estimated $268K.
Valence8 US first reported a position in Intellia Therapeutics in Q3 2024 and held it in 1 quarter.
Valence8 US's Intellia Therapeutics position peaked at $268K in Q3 2024.
293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2024.

Based on Valence8 US's 13F filing for Q4 2024, filed 12 Feb 2025.